In a report released today, Mark Breidenbach from Oppenheimer maintained a Buy rating on Mustang Bio (MBIO – Research Report), with a price target of $16.00. The company’s shares closed last Monday at $3.80.
According to TipRanks.com, Breidenbach is a 4-star analyst with an average return of 8.3% and a 43.8% success rate. Breidenbach covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Iovance Biotherapeutics, and Allogene Therapeutics.
Currently, the analyst consensus on Mustang Bio is a Strong Buy with an average price target of $10.00, a 160.4% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $7.00 price target.
Based on Mustang Bio’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $10.17 million. In comparison, last year the company had a GAAP net loss of $11.77 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies.